logo

For the Inventor, By the Inventor

Mississauga, Canada

Allelix Biopharmaceuticals Inc.

Calculating rank
USPTO Granted Patents = 69


Forward Citations = 632

Loading Chart...
Loading Chart...

66 inventors (with patents filed for the assignee):

goldMedal Sumanas Rakhit (17 out of 17 patents)

silverMedal Rajender Kamboj (15 out of 33 patents)

bronzeMedal Ashok Tehim (12 out of 71 patents)

4.  Stephen L Nutt (12 out of 25 patents)

5.  Jian-Min Fu (10 out of 10 patents)

6.  Abdelmalik Slassi (7 out of 59 patents)

7.  Martin Sumner-Smith (6 out of 14 patents)

8.  Candace E Elliott (6 out of 19 patents)

9.  Michael A Wosnick (6 out of 6 patents)

10.  Lee Shekter (6 out of 6 patents)

11.  Louise G Edwards (5 out of 37 patents)

12.  Geoffrey L Hammond (5 out of 5 patents)

13.  Donald G Munroe (3 out of 8 patents)

14.  Tejal B Vyas (3 out of 7 patents)

15.  Anne E Goodbody (3 out of 5 patents)


Core Competencies:
Dopamine Receptor
Polynucleotides
Antiviral Compounds
5-HT Receptor
Muscarinic Receptor
Glucagon-like Peptide
CNS Receptors
Inhibitors
Pharmaceutical Compositions
Osteogenic Factor
EGF Variants
HIV Replication

69 patents:

1. 6136544 - Glutamate receptor (or EAA receptor) polynucleotides and their uses (2000-10-24),
2. 6133287 - Piperidine-indole compounds having 5-HT.sub.6 affinity (2000-10-17),
3. 6103715 - Dopamine receptor ligands (2000-08-15),
4. 6100291 - Pyrrolidine-indole compounds having 5-HT.sub.6 affinity (2000-08-08),
5. 6077949 - Cloned glucagon-like peptide 2 receptors (2000-06-20),
6. 6057126 - Mammalian EDG-5 receptor homologs (2000-05-02),
7. 6040175 - AMPA-binding human GluR2 receptors (2000-03-21),
8. 6020158 - Isolated polynucleotide for novel G-protein coupled receptor (2000-02-01),
9. 6018023 - Kainate-binding, human CNS receptors of the EAA3 family (2000-01-25),
10. 6013768 - Kainate-binding human CNS receptors of the EAA1 family (2000-01-11),
11. 5998462 - 5-alkyl indole compounds (1999-12-07),
12. 5998438 - 5-cyclo indole compounds (1999-12-07),
13. 5981704 - Kainate-binding, human CNS receptors of the EAA2 family (1999-11-09),
14. 5968478 - N- methyl piperazine compounds having dopamine receptor affinity (1999-10-19),
15. 5856510 - 5-alkenyl and 5-alkynyl indole compounds (1999-01-05),
Company Overview
Allelix Biopharmaceuticals Inc., based in Mississauga, Canada, specializes in the development of innovative therapeutics targeting dopamine receptors and other critical pathways in the central nervous system. The company focuses on creating advanced ligands and inhibitors that address various neurological and psychiatric disorders. Its research encompasses a range of technologies, including polynucleotides and antiviral compounds, contributing to the understanding and treatment of complex health conditions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

69 Patents

#11 in Mississauga

#193 in Canada

#10,778 in the World

Mississauga, CA
Mississauga, Canada

Allelix Biopharmaceuticals Inc.

Forward Citations = 632

66 inventors:

goldMedal Sumanas Rakhit (17 out of 17 patents)

silverMedal Rajender Kamboj (15 out of 33 patents)

bronzeMedal Ashok Tehim (12 out of 71 patents)

4.  Stephen L Nutt (12 out of 25 patents)

5.  Jian-Min Fu (10 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Allelix Biopharmaceuticals Inc.. Retrieved from https://idiyas.com/company/allelix-biopharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…